2006

  • Schneider T, Sailer M, Ansorge S, Firsching R, Reinhold D. Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma. J Neurooncol. 2006 Aug;79(1):61-5
  • Bank U, Tadje J, Helmuth M, Stefin S, Täger M, Wolke C, Wischeropp A, Ittenson A, Reinhold D, Ansorge S, Lendeckel U. Dipeptidylpeptidase IV (DPIV) and alanyl-aminopeptidases (AAPs) as a new target complex for treatment of autoimmune and inflammatory diseases-proof of concept in a mouse model of colitis. Adv Exp Med Biol. 2006;575:143-53
  • Thielitz A, Reinhold D, Vetter R, Lendeckel U, Kahne T, Bank U, Helmuth M, Neubert K, Faust J, Hartig R, Wrenger S, Zouboulis CC, Ansorge S, Gollnick H. Possible role of DP IV inhibitors in acne therapy. Adv Exp Med Biol. 2006;575:163
  • Biton A, Bank U, Täger M, Ansorge S, Reinhold D, Lendeckel U, Brocke S. Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation. Adv Exp Med Biol. 2006;575:177-86
  • Preller V, Gerber A, Togni M, Wrenger S, Schraven B, Rocken C, Marguet D, Ansorge S, Brocke S, Reinhold D. CD26/DP IV in T cell activation and autoimmunity. Adv Exp Med Biol. 2006;575:187-93
  • Thielitz A, Reinhold D, Vetter R, Bank U, Helmuth M, Hartig R, Wrenger S, Wiswedel I, Lendeckel U, Kahne T, Neubert K, Faust J, Zouboulis CC, Ansorge S, Gollnick H. Inhibitors of Dipeptidyl Peptidase IV and Aminopeptidase N Target Major Pathogenetic Steps in Acne Initiation. J Invest Dermatol. 2006 Jun 15
  • Schild L, Bukowska A, Gardemann A, Polczyk P, Keilhoff G, Täger M, Dudley SC, Klein HU, Goette A, Lendeckel U. Rapid pacing of embryoid bodies impairs mitochondrial ATP synthesis by a calcium-dependent mechanism--a model of in vitro differentiated cardiomyocytes to study molecular effects of tachycardia. Biochim Biophys Acta. 2006 Jun;1762(6):608-15
  • Bank U, Heimburg A, Helmuth M, Stefin S, Lendeckel U, Reinhold D, Faust J, Fuchs P, Sens B, Neubert K, Täger M, Ansorge S. Triggering endogenous immunosuppressive mechanisms by combined targeting of Dipeptidylpeptidase IV (DPIV / CD26) and Aminopeptidase N (APN / CD13)- a novel approach for the treatment of inflammatory bowel disease. Int Immunopharmacol 2006 Dec 20; 6 (13-14): 1925-34
  • Reinhold D, Biton A, Pieper S, Lendeckel U, Faust J, Neubert K, Bank U, Täger M, Ansorge S, Brocke S. Dipeprtidyl peptidase IV (DPIV / CD26) and Aminopeptidase N (APN / CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation. Int Immunopharmacol 2006 Dec 20; 6 (13-14): 1935-42